Ultragenyx price target raised to $80 from $71 at Wedbush. Wedbush analyst David raised his price target for Ultragenyx to $80 from $71 after the company reported a solid start to Crysvita sales in the U.S., with rate of adult adoption and reimbursement particularly encouraging for potential growth opportunity. The analyst reiterates an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.